Expression of hepatocyte growth factor activator inhibitor Type-1 (HAI-1) in prostate cancer

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 575-582

  Yasuda, Kenji ^a   Komiya, Akira ^a   Watanabe, Akihiko ^a   Morii, Akihiro ^a   Oya, Takeshi ^b   Nagakawa, Osamu ^a   Fujiuchi, Yasuyoshi ^a   Fuse, Hideki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Niigata Prefectural Central Hospital   (Japan)

Author keywords

Castration resistant prostate cancer; CRPC; HAI 1; Prostate cancer

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR TYPE 1; PROSTATE SPECIFIC ANTIGEN; SCATTER FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TRANSRECTAL ULTRASONOGRAPHY;

AGED; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; TUMOR MARKERS, BIOLOGICAL;

EID: 84875909537     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Tajima H, Matsumoto K and Nakamura T: Regulation of cell growth and motility by hepatocyte growth factor and receptor expression in various cell species. Exp Cell Res 202: 423-431, 1992.
2. Humphrey AP, Zhu X, Zanegar R, Swanson PE, Ratliff TL, Vollmer RT and Day ML: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147: 386-396, 1995.
3. Nishimura K, Kitamura M, Takada S, Nonomura N, Tsujimura A, Matsumiya K, Miki T, Matsumoto K and Okuyama A: Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor. Int J Urol 5: 276-281, 1998.
4. Zhu X and Humphrey PA: Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 56: 1071-1074, 2000.
5. Fujiuchi Y, Nagakawa O, Murakami K, Fuse H and Saiki I: Effect of hepatocyte growth factor on invasion of prostate cancer cells. Oncology Rep 10: 1001-1006, 2003.
6. Hall CL, Tsan R, Mugnai G, Mazar A, Radinsky R and Pettaway CA: Enhanced invasion of hormone refractory-prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinasetype plasminogen activator (u-PA). Prostate 59: 167-176, 2004.
7. Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT and Humphrey PA: Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol 165: 1325-1328, 2001.
8. Kataoka H, Hamasuna R, Itoh H, Kitamura N and Koono M: Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res 60: 6148-6159, 2000.
9. Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y and Kitamura N: Molecular cloning and sequence analysis of the cDNA for a human seine protease responsible for activation of hepatocyte growth factor. Structural similarity for the protease precursor to blood coagulation factor XII. J Biol Chem 268: 10024-10028, 1993.
10. Miyazawa K, Shimomura T and Kitamura A: Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J Biol Chem 271: 3615-3618, 1996.
11. Lee S, Dickson RB and Lin CY: Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275: 36720-36725, 2000.
12. Yasuda K, Nagakawa O, Akashi T, Fujiuchi Y, Koizumi K, Komiya A, Saiki I and Fuse H: Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Prostate 69: 346-351, 2009.
13. Shimomura T, Denda K, Kitamura A, Kwaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K and Kitamura N: Hepatocyte growth factor activator inhibitor, a novel Kunitztype serine protease inhibitor. J Biol Chem 272: 6370-6376, 1997.
14. Kawaguchi T, Qin L, Shimomura T, Kondo K, Matsumoto K, Denda K and Kitamura N: Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitztype serine protease inhibitor. J Biol Chem 272: 27558-27564, 1997.
15. Oberst M, Anders A, Xie B, Singh B, Ossandon M, Johnson M, Dickson RB and Lin CY: Matriptase and HAI1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 158: 1301-1311, 2001.
16. Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, Fuse H and Saiki I: Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 155: 173-179, 2000.
17. Nagata K, Hirono S, Ido A, Kataoka H, Moriuchi A, Shimomura T, Hori T, Hayashi K, Koono M, Kitamura N and Tsubouchi H: Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 289: 205-211, 2001.
18. Parr C, Watkins G, Mansel RE and Jiang WG: The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10: 202-211, 2004.
19. Kataoka H, Miyata S, Uchinokura S and Itoh H: Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 22: 223-236, 2003.
20. Yamauchi M, Kataoka H, Itoh H, Seguchi T, Hsaui Y and Osada Y: Hepatocyte growth factor activator inhibitor type 1 and 2 are expressed by tubular epithelium in kidney and down regulated in renal cell carcinoma. J Urol 171: 890-896, 2004.
21. Itoh H, Kataoka H, Tomita M, Hamasuna R, Nawa Y, Kitamura N and Koono M: Up-regulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa. Am J Physiol Gastrointest Liver Physiol 278: 635-643, 2000.
22. Zeng L, Cao J and Zhang X: Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol 11: 6202-6207, 2005.
23. Nagakawa O, Yamagishi T, Fujiuchi Y, Junicho A, Akashi T, Nagaike K and Fuse H: Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer. Eur Urol 48: 686-690, 2005.
24. Nagakawa O, Yamagishi T, Akashi T, Nagaike K and Fuse H: Serum hepatocyte growth factor activator inhibitor type 1 (HAI-1) and type 2 (HAI-2) in prostate cancer. Prostate 66: 447-452, 2006.
25. Jewett HJ: The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 2: 105-24, 1975.
26. General Rule for Clinical and Pathological Studies on Prostate Cancer. 3rd edition. The Japanese Urological Association, the Japanese Society of Pathology, and Japan Radiological Society, Kanehara-shuppan, Tokyo, p. 44-45, 2001.
27. General Rule for Clinical and Pathological Studies on Prostate Cancer. 4th edition. The Japanese Urological Association, the Japanese Society of Pathology, and Japan Radiological Society, Kanehara-shuppan, Tokyo, p. 92, 2010.
28. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF and Mukhtar H: A novel biomarker for staging human prostate adenocarcinoma: Overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 15: 217-227, 2006.
29. Knudsen BS, Lucas JM, Fazil L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS and Ayala GE: Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol 167: 255-266, 2005.
30. Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N, Miyazawa K and Koono M: Hepatocyte growth factor activator inhibitor type 1 is a specific cell-surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenviroment. J Biol Chem 275: 40453-40462, 2000.
31. Nakamura K, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H and Hiramatsu Y: The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer. Int J Oncol 35: 239-248, 2009.
32. Nakamura K, Hongo A, Kodama J and Hiramatsu Y: The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer. Int J Cancer 128: 2613-2624, 2011.
33. Fukushima T, Kawaguchi M and Yamasaki M: Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells. Cancer Sci 102: 407-413, 2011.
34. Verras M, Lee J, Xue H, Li TH, Wang Y and Sun Z: The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 67: 967-975, 2007.
35. Singh AP, Bafna S, Chaudhary K, Venkatraman G, Smith L, Eudy JD, Johansson SL, Lin MF and Batra SK: Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgenindependent prostate cancer cells. Cancer Lett 259: 28-38, 2008.
36. Nakashiro K, Hayashi Y and Oyasu R: Immunohistochemical expression of hepatocyte growth factor and c-MET/HGF receptor in benign and malignant human prostate tissue. Oncol Rep 10: 1149-53, 2003.
37. Maeda A, Nakashiro K, Hara S, Sasaki T, Miwa Y, Tanji N, Yokoyama M, Hamakawa H and Oyasu R: Inactivation of AR activates HGF/c-MET system in human prostatic carcinoma cells. Biochem Biophy Res Commun 347: 1158-1165, 2006.
38. Tu WH, Zhu C, Clark C, Christensen JG and Sun Z: Efficacy of c-MET inhibitor for advanced prostate cancer. BMC Cancer 10: 556, doi:10.1186/1471- 2407-10-556, 2010.
39. Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, Gordon MS, Haas NB, Harzstark, AL, Kurzrock R, Lara P, Lin C, Sella A, Small EJ, Spira AI, Vaishampayan UN, Vogelzang NJ, Scheffold C, Ballinger MD, Schimmoller F and Smith DC: Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol 29(Suppl): abstr 4516, 2011.
40. Adamo V, Noto L, Franchina T, Chiofalo G, Picciotto M, Toscano G and Caristi N: Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol 3: 73, doi: 10.3389/fendo.2012.00073, 2012.